CLINICAL TRIALS PROFILE FOR QUIZARTINIB DIHYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for quizartinib dihydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00462761 ↗ | A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status | Completed | Daiichi Sankyo Inc. | Phase 1 | 2007-01-01 | Patients received oral AC220 daily for 14 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3 status. |
| NCT00462761 ↗ | A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status | Completed | Daiichi Sankyo, Inc. | Phase 1 | 2007-01-01 | Patients received oral AC220 daily for 14 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3 status. |
| NCT01390337 ↗ | A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | Completed | Ambit Biosciences Corporation | Phase 1 | 2011-10-01 | The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation. |
| NCT01390337 ↗ | A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | Completed | Daiichi Sankyo Inc. | Phase 1 | 2011-10-01 | The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation. |
| NCT01390337 ↗ | A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | Completed | Daiichi Sankyo, Inc. | Phase 1 | 2011-10-01 | The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation. |
| NCT01411267 ↗ | AC220 for Children With Relapsed/Refractory ALL or AML | Completed | Ambit Biosciences Corporation | Phase 1 | 2011-09-01 | This is a phase I study of the investigational drug AC220 combined with cytarabine and etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML). |
| NCT01411267 ↗ | AC220 for Children With Relapsed/Refractory ALL or AML | Completed | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 | 2011-09-01 | This is a phase I study of the investigational drug AC220 combined with cytarabine and etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for quizartinib dihydrochloride
Condition Name
Clinical Trial Locations for quizartinib dihydrochloride
Trials by Country
Clinical Trial Progress for quizartinib dihydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for quizartinib dihydrochloride
Sponsor Name
